X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JNT-517 is a, oral small-molecule, phenylalanine (Phe) transporter SLC6A19 inhibitor, a potential therapy used to treat PKU, regardless of age or genotype. JNT-517 acts at a novel, cryptic allosteric site to block kidney reabsorption of Phe and reduces blood Phe levels.
Lead Product(s): JNT-517
Therapeutic Area: Genetic Disease Product Name: JNT-517
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
The proceeds from the funding will be used to progress the company’s lead program JNT-517 in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and potential first-in-class medicines in immune-mediated diseases and cancer.
Lead Product(s): JNT-517
Therapeutic Area: Genetic Disease Product Name: JNT-517
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $107.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 15, 2022
Details:
Jnana to leverage its RAPID chemoproteomics platform to discover novel small molecule drugs directed to targets across a diverse range of target classes in cancer, immune-mediated and neurological diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $2,050.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration November 15, 2022
Details:
JNT-517, is a small molecule, allosteric inhibitor of SLC6A19, a metabolite transporter responsible for reabsorption of phenylalanine (Phe) in the kidney.
Lead Product(s): JNT-517
Therapeutic Area: Genetic Disease Product Name: JNT-517
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
Discovery of JNT-517, which targets SLC6A19, is based on Jnana’s pioneering research and was enabled by RAPID, company’s high-throughput screening-enabled chemoproteomic platform for treatment of PKU and, Phase 1 clinical study of JNT-517, expected to begin late this year.
Lead Product(s): JNT-517
Therapeutic Area: Genetic Disease Product Name: JNT-517
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Details:
Proceeds from this financing will enable Jnana to progress its lead program, SLC6A19 for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 18, 2021
Details:
Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,040.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
